SG10201913501RA - Liposomal formulations - Google Patents
Liposomal formulationsInfo
- Publication number
- SG10201913501RA SG10201913501RA SG10201913501RA SG10201913501RA SG10201913501RA SG 10201913501R A SG10201913501R A SG 10201913501RA SG 10201913501R A SG10201913501R A SG 10201913501RA SG 10201913501R A SG10201913501R A SG 10201913501RA SG 10201913501R A SG10201913501R A SG 10201913501RA
- Authority
- SG
- Singapore
- Prior art keywords
- liposomal formulations
- liposomal
- formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1277—Processes for preparing; Proliposomes
- A61K9/1278—Post-loading, e.g. by ion or pH gradient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/0067—Catheters; Hollow probes characterised by the distal end, e.g. tips
- A61M25/0082—Catheter tip comprising a tool
- A61M25/0084—Catheter tip comprising a tool being one or more injection needles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M25/104—Balloon catheters used for angioplasty
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Biophysics (AREA)
- Pulmonology (AREA)
- Dispersion Chemistry (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SG10201607641Q | 2016-09-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201913501RA true SG10201913501RA (en) | 2020-03-30 |
Family
ID=61619692
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201913501RA SG10201913501RA (en) | 2016-09-14 | 2017-09-14 | Liposomal formulations |
SG11201901097TA SG11201901097TA (en) | 2016-09-14 | 2017-09-14 | Liposomal formulations |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201901097TA SG11201901097TA (en) | 2016-09-14 | 2017-09-14 | Liposomal formulations |
Country Status (5)
Country | Link |
---|---|
US (1) | US20190216735A1 (en) |
EP (1) | EP3512503A4 (en) |
CN (1) | CN109789093A (en) |
SG (2) | SG10201913501RA (en) |
WO (1) | WO2018052373A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4015008A1 (en) | 2018-05-17 | 2022-06-22 | Hollister Incorporated | Package containing hydrophilic urinary catheter and foamed hydration medium for its hydration |
IT202000007228A1 (en) * | 2020-04-06 | 2021-10-06 | Diego Dolcetta | ADMINISTRATION OF mTOR INHIBITORS IN THE CENTRAL NERVOUS SYSTEM |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5855911A (en) * | 1995-08-29 | 1999-01-05 | Board Of Regents, The University Of Texas System | Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides |
EP1159962A4 (en) * | 1999-03-11 | 2003-07-02 | Fujisawa Pharmaceutical Co | Liposome preparations |
NZ548195A (en) * | 2004-01-14 | 2011-01-28 | Gilead Sciences Inc | Lipid-based dispersions useful for drug delivery |
US20100129414A1 (en) * | 2008-11-24 | 2010-05-27 | Medtronic Vascular, Inc. | Bioactive Agent Delivery Using Liposomes in Conjunction With Stent Deployment |
EP2638896A1 (en) * | 2012-03-14 | 2013-09-18 | Bioneer A/S | Cationic liposomal drug delivery system for specific targeting of human cd14+ monocytes in whole blood |
PL2992874T3 (en) * | 2013-04-30 | 2019-01-31 | Delta-Fly Pharma, Inc. | Liposome for topical administration and application thereof |
-
2017
- 2017-09-14 SG SG10201913501RA patent/SG10201913501RA/en unknown
- 2017-09-14 CN CN201780056778.6A patent/CN109789093A/en active Pending
- 2017-09-14 SG SG11201901097TA patent/SG11201901097TA/en unknown
- 2017-09-14 US US16/332,725 patent/US20190216735A1/en not_active Abandoned
- 2017-09-14 WO PCT/SG2017/050461 patent/WO2018052373A1/en unknown
- 2017-09-14 EP EP17851186.1A patent/EP3512503A4/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
CN109789093A (en) | 2019-05-21 |
SG11201901097TA (en) | 2019-03-28 |
EP3512503A4 (en) | 2020-05-06 |
US20190216735A1 (en) | 2019-07-18 |
WO2018052373A1 (en) | 2018-03-22 |
EP3512503A1 (en) | 2019-07-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL273541A (en) | Formulations | |
IL268697A (en) | Formulations | |
IL269630A (en) | Niraparib formulations | |
IL269621A (en) | Niraparib formulations | |
IL265609A (en) | Novel formulations | |
GB201607918D0 (en) | Novel formulations | |
IL273282A (en) | Niraparib formulations | |
EP3265059A4 (en) | Combination liposomal pharmaceutical formulations | |
GB201608356D0 (en) | Formulation | |
SG10201913501RA (en) | Liposomal formulations | |
HK1250338A1 (en) | Liposomal adjuvant compositions | |
IL252955B (en) | Mouthrinse formulations | |
GB201707615D0 (en) | Formulation | |
GB201805338D0 (en) | Cosmetic formulations | |
GB201621277D0 (en) | Formulations | |
PL3559185T3 (en) | Clear-rinse formulation | |
GB201618110D0 (en) | Formulations | |
GB201616366D0 (en) | Formulations | |
GB201615754D0 (en) | Formulations | |
GB201714461D0 (en) | Formulations | |
ZA201703472B (en) | Mouthrinse formulations | |
GB201617866D0 (en) | Novel formulations | |
GB201616509D0 (en) | Novel formulations | |
GB201609925D0 (en) | Formulation | |
GB201610440D0 (en) | Pharmaceutical formulations |